Hepalys
hepalys.com
Actively hiring
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Overview
Accelerating access to novel therapies for Asian patients with liver disease At Hepalys Pharma, we are committed to improving the lives of patients in Japan and Asia through the development of innovative therapeutics for liver disease.
News
Inventiva and Hepalys Pharma, Inc. announce the initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 trial
Initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 studyPositive results could support the initiation of a pivotal Phase 3 trial in patients in Japan with MASHThe study represents th
Read more
Report
Inventiva and Hepalys Pharma, Inc. announce the initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 trial
Initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 study Positive results could support the initiation of a pivotal Phase 3 trial in patients in Japan with MASH The study represents
Read more
Report
Inventiva and Hepalys Pharma, Inc. announce exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South Korea
Hepalys Pharma, Inc. is a new company created by Catalys Pacific and in which Inventiva has a 30% ownership position. Under the exclusive licensing agreement, Inventiva will receive a $10 million upfront payment, and is eligible to receive up to $ 231 mil
Read more
Report
Report
INVENTIVA: Inventiva and Hepalys Pharma, Inc. announce exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South Korea
Hepalys Pharma, Inc. is a new company created by Catalys Pacific and in which Inventiva has a 30% ownership position. Under the exclusive licensing agreement, Inventiva will receive a $10 million upfront
Read more
Report
Inventiva and Hepalys Pharma, Inc. announce exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South Korea - Company Announcement - FT.com
The latest company information, including net asset values, performance, holding & sectors weighting, changes in voting rights, and directors and dealings.
Read more
Report